GlecaprevirMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3224398/fr/maviret
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
glecaprevir and pibrentasvir
Glecaprevir/Pibrentasvir
glecaprevir
pibrentasvir
antiviral agents
insurance, health, reimbursement
Duration of treatment (qualifier value)
hepatitis C, chronic
glecaprevir
benzimidazoles
quinoxalines
sulfonamides
glecaprevir and pibrentasvir
drug combinations
pyrrolidines

---
https://www.has-sante.fr/jcms/p_3114485/fr/maviret
2019
false
false
false
France
glecaprevir and pibrentasvir
adult
adolescent
hepatitis C, chronic
glecaprevir
pibrentasvir
antiviral agents
insurance, health, reimbursement
treatment outcome
administration, oral
evaluation of the transparency committee
glecaprevir
quinoxalines
sulfonamides
benzimidazoles
glecaprevir and pibrentasvir
drug combinations
pyrrolidines

---
https://www.has-sante.fr/jcms/p_3114479/fr/maviret
2019
false
false
false
France
French
insurance, health, reimbursement
treatment outcome
antiviral agents
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
glecaprevir
pibrentasvir
administration, oral
glecaprevir and pibrentasvir
hepatitis C, chronic
adult
adolescent
renal insufficiency, chronic
Duration of treatment (qualifier value)
glecaprevir
quinoxalines
sulfonamides
benzimidazoles
glecaprevir and pibrentasvir
drug combinations
pyrrolidines

---
Maviret - glecaprevir / pibrentasvir
https://www.ema.europa.eu/medicines/human/EPAR/Maviret
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
treatment outcome
product surveillance, postmarketing
drug combinations
antiviral agents
antiviral agents
tablets
administration, oral
hepatitis C, chronic
adult
drug interactions
pregnancy
breast feeding
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
drug evaluation, preclinical
glecaprevir and pibrentasvir
benzimidazoles
benzimidazoles
glecaprevir
glecaprevir
pibrentasvir
pibrentasvir
glecaprevir
glecaprevir
quinoxalines
sulfonamides
quinoxalines
sulfonamides
glecaprevir and pibrentasvir
pyrrolidines

---
https://www.has-sante.fr/portail/jcms/c_2818016/fr/maviret
https://www.has-sante.fr/portail/jcms/c_2818016/fr/maviret-glecaprevir-/pibrentasvir-association-fixe-d-antiviraux-a-action-directe
2017
false
false
false
false
French
treatment outcome
drug combinations
antiviral agents
antiviral agents
administration, oral
hepatitis C, chronic
adult
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
glecaprevir and pibrentasvir
evaluation of the transparency committee
insurance, health, reimbursement
glecaprevir
glecaprevir
benzimidazoles
benzimidazoles
guidelines for drug use
pibrentasvir
pibrentasvir
glecaprevir
glecaprevir
quinoxalines
sulfonamides
quinoxalines
sulfonamides
glecaprevir and pibrentasvir
pyrrolidines

---